Synaptamide

Research use only, not for human use.

An endogenous DHA metabolite that promotes neurite growth, synaptogenesis, and synaptic function both in vitro and in vivo.

An endogenous DHA metabolite that promotes neurite growth, synaptogenesis, and synaptic function both in vitro and in vivo; significantly increased the number of MAP2 and Tuj-1-positive neurons with concomitant induction of PKA/CREB phosphorylation at low nM; induces neuronal differentiation of NSCs.

Synaptamide (Dehydroepiandrosteron; DHEA) is a weak agonist at both CB1 and CB2 receptors.

Synaptamide (10 mg/kg; subcutaneously; daily for 7 days) promotes cognitive recovery in rats subjected to mild traumatic brain injury (mTBI).Synaptamide (2-10 mg/kg; adult male C57BL/6J mice) reduced the levels of nociceptive and inflammatory pain-related behaviour over 60 min in the intraplantar formaldehyde assay via both intraperitoneal and local intraplantar administration. Animal Model:Male Wistar rats;260?±?20 g, age 3 months; mTBI model)Dosage:10 mg/kg Administration:Subcutaneously; daily for 7 days Result:Reversed the mTBI-induced cognitive deficits.

Docosahexaenoyl ethanolamide

Apoptosis

PKA

PKA

Neurological Disease

——

162758-94-3

371.5561

C24H37NO2

>98% (HPLC)

10 mM in DMSO; Ethanol: 25 mg/mL

CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)NCCO

4,7,10,13,16,19-Docosahexaenamide, N-(2-hydroxyethyl)-, (4Z,7Z,10Z,13Z,16Z,19Z)-

(-20℃)

With Ice Pack

≥ 2 years